Biopharm Services and McMaster University is kicking off the collaboration project to conduct Cell Therapy and Gene Therapy modelling together. Here is our interview with them. Good morning to you, David. Would you kindly introduce yourself to our audience? I’m an
What is your name and your involvement to SDD™? My name is Javier Lozano, I am the Technical Lead for the SDD™ innovation, as well as the Process Engineering Head of Department for PM Group in the UK. Can you explain about SDD™ – what
The historical development of antibody drug conjugates is a well told yarn, where self-immolating reactions are scribbled on ESACT conference paper with PEGS free-issue pens. These multidisciplinary scientists and the molecules they make are writing a new storyline now. Increased activity With six approvals of
General questions What are your name, organization name and position? D Alessandro Luigi Cataldo, PhD candidate at the University of Natural Resources and Life Sciences Vienna (when the interview has been conducted Summer 2020, Alessandro was still at BOKU University; he
With Regeneron’s high profile, single-person, single-site, clinical trial proving successful (along with much supporting other clinical data!), will neutralising antibodies surf the second wave? Our COVID-related blogs focus on capacity and cost of making the treatments and understanding opportunities or bottlenecks in large scale provision
General questions What is your name, company name and position? D Dr David Pollard, Head of Advanced Materials and Processing, which is one of the three pillars of the newly formed Sartorius Corporate Research. The other two pillars of corporate research
Are you interested in optimising performance of your upstream biologics manufacturing? Cell retention/media perfusion devices increase the viable cell density of bioreactors and can be used to reduce the number or volume of seeding stages of the production bioreactor (1,2,3). Additionally, the production cycle can
A Case Study based on the Covid-19 vaccine being developed by the Jenner Institute, Oxford University. An affordable, global vaccine for Covid-19 is still seen as the best chance of protecting vulnerable people and populations at the same time as getting everyone back to normal
The biopharmaceutical industry is investigating various biologics as treatments for COVID-19. This blog looks at the scale of global manufacturing that may be required and the associated cost of goods of these drug products for COVID-19. Vaccine manufacturing will be discussed in a separate blog.
Biopharmaceutical manufacturing capacity, efficiency, flexibility and economics are all important outputs for organisations to optimize and continuously review. BioSolve Process is the biopharmaceutical industry’s most powerful software for bioprocess analysis. Due to the complexity of therapeutic manufacturing there are many variables contributing to the overall
